Compare Lucid Group Inc (LCID) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Sanofi SA — how do they compare? Lucid Group Inc trades at $3.79 (market cap $1.51B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 63× Lucid Group Inc's market cap, and Sanofi SA pays a 6.01% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Sanofi SA for 94 Days on average.
| LCID | SNY | |
|---|---|---|
Market Cap | $1.51B | $95.18B |
Volume | 12,333,745 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $52.34 |
52-Week Low | $3.79 | $39.51 |
Typical Hold Time | 45 Days | 94 Days |
Enterprise Value | $4.40B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.82, down 1.8% with a bearish technical outlook. The company faces significant financial challenges with negative profit margins (-249.21% net income margin) and consecutive earnings misses. Recent developments include strategic partnerships for autonomous vehicles and software updates, but cash burn remains elevated at -$2.93B operating cash flow in 2025.
LCID presents high-risk turnaround potential with analyst consensus target of $7.60 (99% upside) but requires successful execution on cost savings and new vehicle launches. Key risks include persistent cash burn, production delays, and competitive EV market pressures. The stock's viability hinges on management's ability to achieve targeted $1.4B cost savings and deliver the delayed Cosmos SUV.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
